- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03119519
Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.
Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer :A Multicenter,Randomized,Controlled,Phase 2 Study.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510515
- Rekruttering
- Nanfang Hospital, Southern Medical University
-
Kontakt:
- Xiaoxia Zhu, M.D.
- Telefonnummer: +862062787696
- E-mail: zhuxx01@126.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female aged 18 to 70 years old;
- Histologically or cytologically confirmed non-small cell lung cancer;
- Stage IV patients with measurable primary tumor and distant metastases number ≤5;
- PS score 0-2;
- Have never received local or systemic anti-cancer treatment, including surgery (biopsy is allowed), first line chemotherapy, targeted therapy or immunotherapy;
- Life expectancy of >3 months;
- Organ function levels must meet the following requirements:
(1)Bone marrow: White blood cell (WBC)≥4.0G/L;neutrophile granulocyte (NEU)≥1.5G/L;platelets (PLT)≥100G/L; hemoglobin (HGB)≥9g/L; (2)Liver and kidney: total bilirubin (TBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT)≤2.0 × the upper limit of normal (ULN);creatinine≤1.5×ULN; 8.Patient must be willing and able to provide written informed consent.
Exclusion Criteria:
- The amount of metastatic focus >5;
- Patient can't tolerate chemotherapy or targeted therapy;
- Local or systemic anti-cancer treatment had been used for the primary foci and metastatic lymph nodes, including surgery (biopsy is allowed), first line chemotherapy, targeted therapy or immunotherapy;
- Previous or concurrent suffered from other malignancies;
- Concurrent with other serious disease that can not be controlled;
- Women who are breast-feeding or pregnant;
- Have an allergy to pemetrexed, cisplatin, taxanes, targeted medicine and contrast agent;
- Patients with poor obedience or researchers think that the patient may not be able to accomplish the whole trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Local Definitive Radiotherapy
Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
|
three-dimensional conformal therapy or intensity modulated radiation therapy
Andre navne:
Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
Andre navne:
|
Aktiv komparator: No Local Definitive Radiotherapy
Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
|
Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progression-free Survival (PFS)
Tidsramme: 5 years
|
Refers to the time from randomization to disease progression or death.
|
5 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Local tumor control
Tidsramme: up to 5 years
|
From time of randomization to time of progression or death(according to RECIST v1.1 [)
|
up to 5 years
|
Oligometastatic foci control
Tidsramme: up to 5 years
|
From time of first chemotherapy or targeted therapy to time of progression or death(according to RECIST v1.1)
|
up to 5 years
|
Thoracic Progression Free Survival
Tidsramme: up to 5 years
|
From time of first chemotherapy or targeted therapy to time of progression or death
|
up to 5 years
|
Overall Survival
Tidsramme: up to 5 years
|
From time of first chemotherapy or targeted therapy to date of death
|
up to 5 years
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Xiaoxia Zhu, Nanfang Hospital of Southern Medical University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- LC2019ZD009
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Local Definitive Radiotherapy
-
Contamac LtdHartwig Research CenterAfsluttet
-
Cancer Institute and Hospital, Chinese Academy...AfsluttetEsophageale neoplasmerKina
-
Cancer Trials IrelandUniversity College Dublin; Technological University DublinRekrutteringNSCLC/Oligometastatisk kræft (enkelt lungelæsion)Irland
-
European Institute of OncologyAssociazione Italiana per la Ricerca sul CancroRekrutteringAdenocarcinom i prostataItalien
-
Contamac LtdAfsluttetSynskorrektionDet Forenede Kongerige
-
AgNovos Healthcare, LLCAfsluttetHoftebrud | Osteoporose, postmenopausalHong Kong
-
Institut für Klinische Krebsforschung IKF GmbH...AstraZeneca; Thoraxklinik-Heidelberg gGmbHRekruttering
-
Memorial Sloan Kettering Cancer CenterRekrutteringNon-Hodgkin lymfom | Non-Hodgkins lymfom, tilbagefald | Non-Hodgkins lymfom refraktærForenede Stater
-
RefleXion MedicalAfsluttetKræft | Tumor, fast | Kræft, lunge | Metastase til knogle | Metastase til lunge | Kræft, BoneForenede Stater
-
Icahn School of Medicine at Mount SinaiRekrutteringHoved- og halspladecellekræft (HNSCC)Forenede Stater